Similar articles

• Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

  Ewer MS, Lippman SM. Ewer MS, et al. J Clin Oncol. 2005 May 1;23(13):2900-2. doi: 10.1200/JCO.2005.05.827. J Clin Oncol. 2005. PMID: 15860848 No abstract available.
• [Cardiotoxicity of cancer therapy].

  Marek J, Linhart A, Rucklová Z, Haber J, Korínek J. Marek J, et al. Vnitr Lek. 2011 May;57(5):472-84. Vnitr Lek. 2011. PMID: 21695928 Review. Czech.
• [Chronic myocardiopathy induced by imipramine].

  Saint-Pierre A, Perrin A, Pouzeratte JP, Favrot B. Saint-Pierre A, et al. Coeur Med Interne. 1972 Jan-Mar;11(1):27-34. Coeur Med Interne. 1972. PMID: 5014849 French. No abstract available.
• [Cardiac tolerance of the combination paclitaxel-anthracyclines in the context of the management of cancer of the breast].

  Ferrero JM, Magné N, Foa C, Largillier R, Namer M. Ferrero JM, et al. Bull Cancer. 2003 Mar;90(3):219-26. Bull Cancer. 2003. PMID: 12801824 Review. French.
• Pathogenesis of cardiotoxicity induced by anthracyclines.

  Elliott P. Elliott P. Semin Oncol. 2006 Jun;33(3 Suppl 8):S2-7. doi: 10.1053/j.seminoncol.2006.04.020. Semin Oncol. 2006. PMID: 16781283 Review.